Semaglutide produces an average of 15 to 17 percent body weight loss in clinical trials, but the spread between patients is wide. Some people lose nothing in the first three months. Others lose more than 25 percent. A common GLP1R variant explains a meaningful portion of that variation in both weight loss and side-effect risk.
Severe abdominal pain that radiates to the back, persistent vomiting, or signs of pancreatitis warrant immediate medical attention. A history of medullary thyroid carcinoma or MEN2 is a contraindication for any GLP-1 agonist.
Semaglutide is titrated slowly to limit nausea. The full Wegovy dose is 2.4 mg weekly, but it takes 16 to 20 weeks of stepping up to get there. Most of the weight loss happens after you reach the maintenance dose, so a flat scale during titration is normal.
Semaglutide curbs appetite, but it doesn't override deliberate calorie intake. Liquid calories (alcohol, sugary drinks, smoothies) bypass the satiety effect almost entirely. Late-evening eating windows, when GLP-1 levels naturally fall, also blunt response.
Steroids, certain antidepressants, and antipsychotics can drive weight gain that offsets the GLP-1 effect. Untreated hypothyroidism, PCOS, and Cushing's syndrome are also common confounders.
GLP1R is the gene that codes for the GLP-1 receptor, which is the direct target of semaglutide. A single common SNP in the signal peptide (rs10305420, called Pro7Leu) changes how efficiently the receptor gets to the cell surface.
The Leu7 allele changes a single amino acid in the signal peptide that guides the GLP-1 receptor to the cell membrane. Carriers of one or two Leu7 alleles tend to have a stronger response to semaglutide. They also have a higher rate of nausea and vomiting, which fits with the model that more receptor signal means both more weight loss and more side effects.
Roughly a third of people of European descent carry at least one Leu7 allele. Heterozygotes (Pro7/Leu7) lose about 0.76 kg more weight than non-carriers; homozygotes (Leu7/Leu7) lose about 1.5 kg more. The variant doesn't determine whether semaglutide will work for you. It changes the size of the typical response and tilts the side-effect profile.
Pharmacogenetic testing is most useful if you've been on the maintenance dose of semaglutide for 8 to 12 weeks with little weight loss, or if nausea has been severe enough that you're considering stopping. Knowing your GLP1R status helps set realistic expectations and informs the decision to try a different drug in the class.
Learn how genetics may affect your response to these related medications:
Probably not, because tirzepatide hits both the GLP-1 and GIP receptors. The GLP1R variant that affects semaglutide also affects tirzepatide's GLP-1 arm, but tirzepatide is also sensitive to a separate GIPR variant that doesn't apply to semaglutide. People who don't tolerate one are sometimes fine on the other.
No. The variant predicts the size and tilt of the response, not whether the drug will work. Most carriers of the Leu7 allele do well on semaglutide and many lose more weight than average. The information is most useful for setting expectations and deciding whether a slower titration is appropriate.
If you tolerate the current dose, dose escalation per the standard schedule is the right next step. If you're already at the maximum approved dose without effect, switching drug class is a more productive move than pushing the dose further off-label.
Find out how your DNA may influence your response to Semaglutide and other medications with a Gene2Rx pharmacogenetics report.
Get Your Report Try Our Free Calculator